RACIAL DIFFERENCES IN THE COST OF TREATING EARLY STAGE PROSTATE CANCER
Author(s)
Brandeis J1, Pashos CL3, Henning JM2, Litwin MS1, 1Departments of Urology and Health Services, University of California, Los Angeles, CA, USA; 2TAP Holdings, Deerfield, IL, USA; 3Abt Associates Clinical Trials, Cambridge, MA, USA
Although race has been associated with differences in the utilization and costs of medical services for a variety of conditions, no study has examined racial differences in the expense of caring for men with early stage prostate cancer. OBJECTIVE: To compare the cost and resource utilization in the work up, treatment and 6 month follow up of African American and white men undergoing either external beam radiation therapy (XRT) or radical prostatectomy for early stage prostate cancer. DESIGN: Retrospective analysis of cost and resource utilization data from encrypted patient-specific hospital inpatient, hospital outpatient, and physician/supplier data files. PARTICIPANTS: A random 5% national sample of Medicare beneficiaries (n=8,750) from the Health Care Financing Administration (HCFA) Public Use Files for calendar years 1993 through 1996. MAIN OUTCOME MEASURES: Inpatient, outpatient and physician/supplier Medicare costs. RESULTS: African American men undergoing radical prostatectomy for early stage prostate cancer had significantly higher costs ($21,878 vs $18,786, p<0.0001) than did white men. Most of the difference occurred in the inpatient setting. African American men undergoing external beam radiation therapy (XRT) had significantly greater costs ($18,131 vs $15,734, p<0.0001) than did white men. Most of this difference was generated by longer duration of XRT treatments. CONCLUSIONS: In early stage prostate cancer, costs of treatment with either radical prostatectomy or XRT in African American men are higher than in white men.
Conference/Value in Health Info
2000-05, ISPOR 2000, Arlington, VA, USA
Value in Health, Vol. 3, No. 2 (March/April 2000)
Code
PCN12
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology